Who is sponsoring NCT04823949?

NCT04823949 is sponsored by Prisma Health-Upstate.

What drugs are being tested in NCT04823949?

Interventions in NCT04823949: Home blood pressure monitoring.

What condition does NCT04823949 study?

NCT04823949 studies Gestational Hypertension, Preeclampsia, Chronic Hypertension With Pre-Eclampsia Complicating Childbirth, HELLP Syndrome.

Is NCT04823949 still recruiting?

NCT04823949 is currently completed. Last updated 18 May 2023.

Are results published for NCT04823949?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2023-05-18 · How we verify

NCT04823949: PHANTOM

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Pregnancy-Related Hypertension: Adherence to a New Type of Monitoring

Completed NA Results posted Last updated 18 May 2023

What this trial tests

NA trial testing Home blood pressure monitoring in Gestational Hypertension in 202 participants. Completed in 18 January 2022.

Timeline

15 April 2021

Primary endpoint
18 January 2022

18 January 2022

Quick facts

Lead sponsor	Prisma Health-Upstate
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	health services research
Enrollment	202
Start date	15 April 2021
Primary completion	18 January 2022
Estimated completion	18 January 2022
Sites	2 locations across United States

Drugs / interventions tested

Home blood pressure monitoring

Conditions studied

Gestational Hypertension — all drugs for Gestational Hypertension →
Preeclampsia — all drugs for Preeclampsia →
Chronic Hypertension With Pre-Eclampsia Complicating Childbirth — all drugs for Chronic Hypertension With Pre-Eclampsia Complicating Childbirth →
HELLP Syndrome — all drugs for HELLP Syndrome →

Sponsor

Prisma Health-Upstate — full company profile →

Who can join

18 and older, female only, with Gestational Hypertension or Preeclampsia. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Adherence to the American College of Obstetricians and Gynecologists Guideline of Postpartum Blood Pressure Check Within 10 Days Postpartum Primary · 10 days

How many participants had a blood pressure check within 10 days postpartum as recommended by the American College of Obstetricians and Gynecologists

Group	Value	95% CI
Standard Care	59
Intervention	89

Initiation of Antihypertensive After Discharge Secondary · 16 days

How many participants required initiation of antihypertensive after discharge

Group	Value	95% CI
Standard Care	7
Intervention	9

Unscheduled Visits Secondary · 16 days

Number of participants with unscheduled visits

Group	Value	95% CI
Standard Care	5
Intervention	12

Readmission Secondary · 6 weeks

Number of participants readmitted postpartum

Group	Value	95% CI
Standard Care	5
Intervention	4

Attended Postpartum Visit Secondary · 6 weeks

Number of participants who attended their postpartum visit

Group	Value	95% CI
Standard Care	71
Intervention	75

Sponsor's own description

A large segment of our patient population is diagnosed with hypertensive disorders of pregnancy, including gestational hypertension and pre-eclampsia. New guidelines from the American College of Obstetricians and Gynecologists recommend postpartum monitoring of blood pressures via blood pressure checks on day 3 postpartum and between days 7-10 postpartum. Our purpose is to compare the effectiveness of using a Bluetooth-enabled home blood pressure monitoring platform to the standard postpartum office-based blood pressure monitoring in performing the recommended postpartum follow-up for patients with hypertensive disorders of pregnancy.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Remote Monitoring Compared With In-Office Surveillance of Blood Pressure in Patients With Pregnancy-Related Hypertension: A Randomized Controlled Trial.
Arkerson BJ, Finneran MM, Harris SR, Schnorr J, et al · · 2023 · cited 27× · PMID 37734091 · DOI 10.1097/aog.0000000000005327

Verify or expand the search:

Other trials of Home blood pressure monitoring

Trials testing the same drug.

NCT04307004 — Evaluating Novel Approaches for Estimating Awake and Sleep Blood Pressure · NA · completed
NCT03524456 — Home Blood Pressure SMS Telemonitoring in the Primary Care Setting · NA · completed
NCT03209154 — An Interventional Multidisciplinary Approach to Individualize Blood Pressure Treatment · NA · active not recruiting

Other recruiting trials for Gestational Hypertension

Currently open trials in the same condition.

NCT06953115 — Vagal Stimulation Therapy and Preeclampsia · NA · recruiting
NCT07041281 — Spironolactone to Improve Pregnancy-Associated Hypertension Trajectories · Phase 2 · recruiting
NCT07349277 — Evaluation of sFlt-1/PlGF Ratio ,OPG and sEng as Predictive Biomarkers in the Diagnosis and Treatment Evaluation of Pree · recruiting
NCT06632379 — AtorvaStatin Postpartum and Reduction of Cardiovascular risK · Phase 4 · recruiting
NCT06814509 — Delivering HOPE (Helping Women Optimize Prenatal Equity) · NA · recruiting

Other Prisma Health-Upstate trials

Trials by the same sponsor.

NCT07202039 — Electronic Cigarettes as a Harm Reduction Strategy Among People With Opioid Use Disorder on Buprenorphine · NA · not yet recruiting
NCT07375212 — VAPorized Administration of Bumetanide for Outpatient Relief in Heart Failure · Phase 4 · withdrawn
NCT07102615 — Intracervical Vasopressin · Phase 4 · recruiting
NCT07101250 — Preoperative Acetazolamide · Phase 4 · recruiting
NCT06874413 — Targeted Prehabilitation With Physical Exercise and Inspiratory Muscle Training for Elderly Frail Patients Prior to Vent · NA · enrolling by invitation

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04823949 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Prisma Health-Upstate
Last refreshed: 18 May 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04823949.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing